Cargando…
Direct non-cyclooxygenase-2 targets of celecoxib and their potential relevance for cancer therapy
Celecoxib (Celebrex®) was developed as a selective cyclooxygenase-2 (COX-2) inhibitor for the treatment of chronic pain. However, it now appears that this compound harbours additional pharmacologic activities that are entirely independent of its COX-2-inhibitory activity. This review presents the re...
| Autor principal: | |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2007
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360267/ https://www.ncbi.nlm.nih.gov/pubmed/17955049 http://dx.doi.org/10.1038/sj.bjc.6604049 |